Monoclonal Antibody Use for Coronavirus Disease 2019 in Pediatric Patients: A Multicenter Retrospective Study

Abstract Monoclonal antibodies for COVID-19 are authorized in high-risk patients aged ≥12 years, but evidence in pediatric patients is limited. In our cohort of 142 patients treated at seven pediatric hospitals between 12/1/20 and 7/31/21, 9% developed adverse events, 6% were admitted for COVID-19 w...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of the Pediatric Infectious Diseases Society Vol. 12; no. 3; pp. 152 - 155
Main Authors:	Sherman, Gilad, Lamb, Gabriella S, Sharma, Tanvi S, Lloyd, Elizabeth C, Nagel, Jerod, Dandam, Nada N, Oliveira, Carlos R, Sheikha, Hassan S, Anosike, Brenda I, Lee, Philip, Vora, Surabhi B, Patel, Karisma, Sue, Paul K, Rubbab, Beenish, Yarbrough, April M, Ganapathi, Lakshmi, Nakamura, Mari M
Format:	Journal Article
Language:	English
Published:	US Oxford University Press 18-04-2023
Subjects:	Antibodies, Monoclonal - therapeutic use Brief Report Child COVID-19 Hospitalization Hospitals, Pediatric Humans Retrospective Studies COVID-19 casirivimab and imdevimab SARS-CoV-2 bamlanivimab and etesevimab monoclonal antibodies pediatric
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Abstract Monoclonal antibodies for COVID-19 are authorized in high-risk patients aged ≥12 years, but evidence in pediatric patients is limited. In our cohort of 142 patients treated at seven pediatric hospitals between 12/1/20 and 7/31/21, 9% developed adverse events, 6% were admitted for COVID-19 within 30 days, and none received ventilatory support or died.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Ganapathi and Nakamura. Co-senior authors.
ISSN:	2048-7207 2048-7193 2048-7207
DOI:	10.1093/jpids/piac124